Let a resubmission be considered when the evidence is ready, not at the next of three meetings
The PBAC meets three times a year. A medicine rejected in March cannot be reconsidered when the additional evidence is ready in May; it waits for July, or more realistically November. Two resubmissions is most of a year in calendar time alone.
Steps this would change
Rationale
This is a narrow proposal about cycle time and it should not be read as anything else. Nothing here criticises the PBAC's judgement, its rigour, or its independence, and a faster committee that reached worse decisions would be a clear loss — the assessment is why Australia gets the prices it does.
The point is the calendar.
The committee meets in March, July and November. On the modelled process a first submission carries about 60 days of averaged waiting for a meeting, which is an ordinary cost of doing business.
The cost compounds on resubmission, which for new medicines is common. A submission not recommended in March is answered by additional evidence or a revised price. That work does not take four months. But the answer cannot be considered until a meeting, so a sponsor ready in May waits for July — and given the lead time for papers, more often for November. Two cycles of that is most of a year in which the only thing happening is the passage of time.
What could change:
- Out-of-cycle consideration for defined resubmission categories — a rejection turning on a discrete question the committee has already framed (a price, a restriction wording, one piece of evidence it asked for) does not need a full meeting agenda slot to resolve.
- A fourth meeting, which is the blunt version and is a resourcing question rather than a design one.
The distinction that makes this defensible is the same one this database applies
to planning panels: where the substantive work is
finished and what remains is waiting for a room, the wait is scheduling, and
scheduling is recoverable without lowering any standard.
Who acts: the Commonwealth, through the department that supports the committee, and the committee itself.
What is being traded away
Committee members are practising clinicians and academics, and the cycle protects the quality of their attention. Three meetings a year with substantial lead time is what makes it possible for busy people to read very large evidence packages properly. Out-of-cycle consideration means asking volunteers to turn around complex material at short notice, and the predictable result of that is either declining participation or less careful reading. Either would cost more than the delay.
Deliberation benefits from being collective and comparative. Considering medicines in batches lets the committee weigh consistency across submissions — is this the same standard we applied to the comparable drug last cycle? Out-of-cycle decisions are made without that context and risk drifting from the line the committee holds in its scheduled work.
Sponsors are not passive in this. Recent academic work on strategic delay in Australian reimbursement argues that timing and pricing choices by sponsors extend negotiations too. Faster resubmission windows would be used by sponsors to run more iterations at lower cost, which may increase the number of resubmissions rather than reduce total elapsed time.
And the honest scale. 180 days on a 930-day path, and most of the addressable time in that process sits in the Cabinet step, not here. This is the smaller of the two PBS proposals and the one more likely to be resisted by the people whose judgement the scheme depends on.
Precedent
Intersessional and out-of-cycle consideration already exists for particular categories of PBAC business. The committee already works between meetings; the question is which matters can be dealt with that way.
Sources
- PBS, published PBAC meeting calendar and cycle timeframes for 2026-2027: three meetings a year
- PBS, TGA and PBAC parallel process factsheet
- Li, 'Strategic Delay and Bargaining Over Public Insurance Coverage for Drugs in Australia', Health Economics, 2026